2025 ISAKOS Biennial Congress ePoster
Clinical Efficacy Of Mocart 2.0 Score And Its Clinically Relevant Cut-Off Value Of 60
Hyun-Soo Moon, MD, PhD, Seoul KOREA, REPUBLIC OF
Min Jung, MD, PhD, Seoul KOREA, REPUBLIC OF
Kwangho Chung, MD, Seoul KOREA, REPUBLIC OF
Se-Han Jung, MD, Seoul KOREA, REPUBLIC OF
Sung-Hwan Kim, MD, PhD, Seoul KOREA, REPUBLIC OF
Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF
FDA Status Not Applicable
Summary
The MOCART 2.0 score positively correlates with clinical outcomes, with scores ≥60 expected to be associated with favorable clinical results.
ePosters will be available shortly before Congress
Abstract
Background
The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) 2.0 score is widely used to assess cartilage repair outcomes, but standardized criteria for its interpretation, especially concerning clinical outcomes, are lacking. Therefore, this study aimed to evaluate the relationship between the MOCART 2.0 score and postoperative clinical outcomes and to determine relevant cut-off values.
Methods
Medical records of patients who underwent cartilage repair for tibiofemoral joint lesions of the knee from 2010 to 2023 were retrospectively reviewed. Patients who underwent concomitant procedures were excluded, and those who took MRI at 1 year postoperatively were included. Clinical outcomes were assessed using the IKDC subjective score, Lysholm score, and KOOS, with respective clinically important difference (CID) and substantial clinical benefit (SCB) values used to assess clinically meaningful improvement. Relationships between these clinical scores and the MOCART 2.0 score were analyzed, with cut-off values evaluated using ROC curve analysis, followed by group comparisons based on the identified cut-off value.
Results
Eighty-eight patients were included. The MOCART 2.0 score showed positive correlations with most clinical scores at 1 year postoperatively. The patients were then categorized based on whether they showed improvement beyond the respective CID and SCB values for each score compared to preoperative status, with regression analyses thereafter revealing significant associations between the MOCART 2.0 score and both the Lysholm score (P = 0.001 for CID, P = 0.032 for SCB) and KOOS symptoms score (P = 0.046 for SCB). Subsequent ROC curve analysis identified a statistically significant cut-off point of 58.8 (relevant for the Lysholm score for both CID and SCB). Reclassified grouping by a threshold of 60, based on its scoring system, showed that patients scoring ≥60 had higher clinical scores and lower osteoarthritis grades at 1 year and the final follow-up.
Conclusion
The MOCART 2.0 score positively correlates with clinical outcomes, with scores ≥60 expected to be associated with favorable clinical results.